Market Closed -
Nyse
16:10:00 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
1.17
USD
|
-0.85%
|
|
+10.38%
|
+7.34%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
133.3
|
264
|
413
|
198.9
|
190.7
|
220.9
|
-
|
-
|
Enterprise Value (EV)
1 |
133.3
|
264
|
413
|
198.9
|
190.7
|
220.9
|
220.9
|
220.9
|
P/E ratio
|
-11.1
x
|
-12.6
x
|
-9.42
x
|
-7.8
x
|
-9.08
x
|
-8.36
x
|
-7.8
x
|
-7.09
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.9
x
|
145
x
|
95.1
x
|
13.5
x
|
21.3
x
|
17.6
x
|
35.8
x
|
7.74
x
|
EV / Revenue
|
37.9
x
|
145
x
|
95.1
x
|
13.5
x
|
21.3
x
|
17.6
x
|
35.8
x
|
7.74
x
|
EV / EBITDA
|
-3.73
x
|
-10.8
x
|
-8.54
x
|
-9.13
x
|
-7.93
x
|
-8.46
x
|
-9.15
x
|
22.5
x
|
EV / FCF
|
-
|
-
|
-
|
308
x
|
-6.52
x
|
-42.5
x
|
-5.6
x
|
-6.1
x
|
FCF Yield
|
-
|
-
|
-
|
0.32%
|
-15.3%
|
-2.35%
|
-17.9%
|
-16.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
149,794
|
149,991
|
168,558
|
169,976
|
174,987
|
188,798
|
-
|
-
|
Reference price
2 |
0.8900
|
1.760
|
2.450
|
1.170
|
1.090
|
1.170
|
1.170
|
1.170
|
Announcement Date
|
20-03-12
|
21-03-11
|
22-03-10
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.515
|
1.826
|
4.341
|
14.7
|
8.945
|
12.53
|
6.171
|
28.54
|
EBITDA
1 |
-35.75
|
-24.34
|
-48.34
|
-21.79
|
-24.04
|
-26.1
|
-24.14
|
9.8
|
EBIT
1 |
-38.88
|
-26.45
|
-49.21
|
-22.52
|
-24.73
|
-26.46
|
-36.4
|
-35.4
|
Operating Margin
|
-1,106%
|
-1,448.36%
|
-1,133.63%
|
-153.17%
|
-276.5%
|
-211.19%
|
-589.94%
|
-124.06%
|
Earnings before Tax (EBT)
1 |
-19.23
|
-21.92
|
-43.27
|
-25.81
|
-23.28
|
-23.82
|
-30.48
|
-33.86
|
Net income
1 |
-11.71
|
-20.65
|
-43.02
|
-26.27
|
-21.49
|
-25.86
|
-30.48
|
-33.86
|
Net margin
|
-333.12%
|
-1,130.83%
|
-990.99%
|
-178.69%
|
-240.2%
|
-206.4%
|
-493.95%
|
-118.65%
|
EPS
2 |
-0.0800
|
-0.1400
|
-0.2600
|
-0.1500
|
-0.1200
|
-0.1400
|
-0.1500
|
-0.1650
|
Free Cash Flow
1 |
-
|
-
|
-
|
0.646
|
-29.24
|
-5.2
|
-39.45
|
-36.2
|
FCF margin
|
-
|
-
|
-
|
4.39%
|
-326.89%
|
-41.5%
|
-639.31%
|
-126.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-12
|
21-03-11
|
22-03-10
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.9
|
2.27
|
1.168
|
5.237
|
4.553
|
2.998
|
1.915
|
2.386
|
3.225
|
1.246
|
2.118
|
1.444
|
0.8613
|
1.38
|
14.48
|
0.4323
|
EBITDA
1 |
-11.89
|
-6.644
|
-28.05
|
-6.214
|
-4.055
|
-5.058
|
-6.466
|
-6.471
|
-4.854
|
-6.529
|
-6.187
|
-6.486
|
-7.495
|
-6.155
|
-5.9
|
-7.38
|
EBIT
1 |
-
|
-6.843
|
-28.24
|
-6.396
|
-4.234
|
-5.251
|
-6.639
|
-6.642
|
-5.024
|
-6.705
|
-6.362
|
-6.661
|
-8.041
|
-8.593
|
23.22
|
-10.35
|
Operating Margin
|
-
|
-301.45%
|
-2,417.64%
|
-122.13%
|
-92.99%
|
-175.15%
|
-346.68%
|
-278.37%
|
-155.78%
|
-538.12%
|
-300.38%
|
-461.29%
|
-933.6%
|
-622.86%
|
160.37%
|
-2,393%
|
Earnings before Tax (EBT)
1 |
-14.96
|
-8.846
|
-28.01
|
-7.093
|
-6.782
|
-5.575
|
-6.362
|
-6.207
|
-5.203
|
-7.158
|
-4.714
|
-6.558
|
-8.177
|
-7.817
|
10.7
|
-9.268
|
Net income
1 |
-14.92
|
-7.823
|
-28.99
|
-7.087
|
-6.763
|
-6.069
|
-6.354
|
-4.372
|
-5.229
|
-7.11
|
-4.775
|
-6.542
|
-8.182
|
-7.804
|
10.7
|
-9.262
|
Net margin
|
-1,657.78%
|
-344.63%
|
-2,482.02%
|
-135.33%
|
-148.54%
|
-202.43%
|
-331.8%
|
-183.24%
|
-162.14%
|
-570.63%
|
-225.45%
|
-453.05%
|
-949.9%
|
-565.66%
|
73.91%
|
-2,142.34%
|
EPS
2 |
-0.1000
|
-0.0500
|
-0.1700
|
-0.0400
|
-0.0400
|
-0.0400
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0400
|
-0.0200
|
-0.0400
|
-0.0450
|
-0.0425
|
0.1300
|
-0.0450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-08-06
|
21-11-10
|
22-03-10
|
22-05-12
|
22-08-11
|
22-11-10
|
23-03-09
|
23-05-11
|
23-08-10
|
23-11-09
|
24-03-07
|
24-05-09
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
0.65
|
-29.2
|
-5.2
|
-39.5
|
-36.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.44
|
-
|
-
|
0.41
|
0.67
|
-
|
-
|
0.5
|
Capex / Sales
|
12.52%
|
-
|
-
|
2.81%
|
7.53%
|
-
|
-
|
1.75%
|
Announcement Date
|
20-03-12
|
21-03-11
|
22-03-10
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Last Close Price
1.17
USD Average target price
5.2
USD Spread / Average Target +344.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.34% | 221M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|